204 related articles for article (PubMed ID: 29299356)
21. Safety and Efficacy of s-MOX Regimen in Patients with Colorectal Cancer Who Developed Cardiotoxicity Following Fluoropyrimidine Administration: A Case Series.
Ehrlich MI; Kaley K; Smith M; Saif MW
Arch Med Case Rep; 2020; 2(1):23-29. PubMed ID: 32964213
[TBL] [Abstract][Full Text] [Related]
22. Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions.
Chong JH; Ghosh AK
Interv Cardiol; 2019 May; 14(2):89-94. PubMed ID: 31178935
[TBL] [Abstract][Full Text] [Related]
23. Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients' heart?
Fontanella C; Aita M; Cinausero M; Aprile G; Baldin MG; Dusi V; Lestuzzi C; Fasola G; Puglisi F
Onco Targets Ther; 2014; 7():1783-91. PubMed ID: 25302025
[TBL] [Abstract][Full Text] [Related]
24. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
[TBL] [Abstract][Full Text] [Related]
25. Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
Upshaw JN; O'Neill A; Carver JR; Dimond EP; Denlinger CS; Kircher SM; Wagner LI; Ky B; Brell JM
Clin Colorectal Cancer; 2019 Mar; 18(1):44-51. PubMed ID: 30348619
[TBL] [Abstract][Full Text] [Related]
26. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Ku GY; Haaland BA; de Lima Lopes G
Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
[TBL] [Abstract][Full Text] [Related]
27. Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.
Punt CJA; Heinemann V; Maughan T; Cremolini C; Van Cutsem E; McDermott R; Bodoky G; André T; Osterlund P; Teske AJ; Pfeiffer P
ESMO Open; 2023 Apr; 8(2):101199. PubMed ID: 37018874
[TBL] [Abstract][Full Text] [Related]
28. Fluoropyrimidine-associated cardiotoxicity: revisited.
Saif MW; Shah MM; Shah AR
Expert Opin Drug Saf; 2009 Mar; 8(2):191-202. PubMed ID: 19309247
[TBL] [Abstract][Full Text] [Related]
29. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
[TBL] [Abstract][Full Text] [Related]
30. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
Deboever G; Hiltrop N; Cool M; Lambrecht G
Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
[TBL] [Abstract][Full Text] [Related]
31. The Incidence of Hematological Toxicities in Colorectal Cancer Patients Treated With Fluoropyrimidine-Based Regimens at Princess Noorah Oncology Center.
Khan M; Alharbi S; Aljuhani S; Tunkar M; Morya A; Alnatsheh A; Alshamrani M; Felemban R
Cureus; 2023 Aug; 15(8):e44267. PubMed ID: 37772227
[TBL] [Abstract][Full Text] [Related]
32. Predicting cardiovascular events with fluoropyrimidine chemotherapy using a standard cardiovascular risk calculator.
Abiodun A; Shawe-Taylor M; Tyebally S; Bagkeris E; Bajomo O; Artico J; Slater S; Raisi-Estabragh Z; Diamantis N; Manisty C
ESC Heart Fail; 2024 Jun; ():. PubMed ID: 38845140
[TBL] [Abstract][Full Text] [Related]
33. 5-fluorouracil and cardiotoxicity: a review.
Sara JD; Kaur J; Khodadadi R; Rehman M; Lobo R; Chakrabarti S; Herrmann J; Lerman A; Grothey A
Ther Adv Med Oncol; 2018; 10():1758835918780140. PubMed ID: 29977352
[TBL] [Abstract][Full Text] [Related]
34. The puzzling clinical presentation of fluoropyrimidines cardiotoxicity.
Cucciniello L; Bidoli E; Viel E; Canale ML; Gerratana L; Lestuzzi C
Front Cardiovasc Med; 2022; 9():960240. PubMed ID: 36186986
[TBL] [Abstract][Full Text] [Related]
35. An unusual case of acute myopericarditis after the first dose of capecitabine: Need for new cardioprotective strategies and risk stratification.
Meter M; Gavran I; Bajo D; Duplancic D
Int J Clin Pharmacol Ther; 2021 Dec; 59(12):775-779. PubMed ID: 34503643
[TBL] [Abstract][Full Text] [Related]
36. A case of capecitabine-induced coronary microspasm in a patient with rectal cancer.
Arbea L; Coma-Canella I; Martinez-Monge R; García-Foncillas J
World J Gastroenterol; 2007 Apr; 13(14):2135-7. PubMed ID: 17465463
[TBL] [Abstract][Full Text] [Related]
37. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
38. Rechallenging Fluoropyrimidine-Induced Cardiotoxicity and Neurotoxicity: A Report of Two Cases.
Ashish S; Raj MS; Monga D; Finley G
Cureus; 2022 Jul; 14(7):e26824. PubMed ID: 35971344
[TBL] [Abstract][Full Text] [Related]
39. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Schöffski P
Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664
[TBL] [Abstract][Full Text] [Related]
40. Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm.
Shah NR; Shah A; Rather A
J Oncol Pharm Pract; 2012 Mar; 18(1):132-5. PubMed ID: 21321041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
